PMGC Holdings Inc. filed an amendment to its Articles of Incorporation on August 31, 2026, to increase the total number of authorized shares of capital stock to 1.5 billion. The amendment, approved by holders representing 60.34% of the voting power, authorizes 1 billion shares of common stock and 500 million shares of preferred stock, each with a par value of $0.0001.
Separately, the company reported on the progress of its subsidiary, NorthStrive Biosciences Inc., which entered into a First Amendment to its Development and License Agreement with Yuva Biosciences on August 27, 2026. The amendment formalizes a three-phase Expansion Program designed to advance four AI-discovered compounds toward lead compound nomination. The program is expected to take approximately six months and will focus on confirming the induction of ANT1, a mitochondrial protein, in differentiated human myotubes.
The amendment also updated the definitions of the exclusive field of use for the compounds, specifically defining it as Cardiac Diseases and Obesity. Furthermore, it grants NorthStrive Biosciences a right of first refusal to negotiate an exclusive license across the broader cardiometabolic field for one year following the completion of Phase III.
